|
|
Article: Biosimilars of TNF-alpha Inhibitors Stand to Erode Over $9 Billion in Brand Sales in the U.S. and Europe by 2018.
- Article from:
- PR Newswire
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Pressure From Payers Will Motivate Surveyed Physicians to Prescribe Biosimilars, According to a New Report From Decision Resources
WALTHAM, Mass., Nov. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.
...